INSYS Therapeutics (INSY +12.5%) is up on double normal volume in apparent response to its announcement of positive data from an early-stage trial assessing its epinephrine nasal spray for the treatment of acute allergic reaction (anaphylaxis).
Results from a pharmacokinetics study in 60 people with seasonal allergies showed that the bioavailability of nasally administered epinephrine was similar to Mylan's (MYL -5.2%) EpiPen administered via intramuscular injection. Rapid drug absorption was also observed.
The company says it plans to work with the FDA to determine the best path to making the product available to consumers considering the current shortage of epinephrine.
Related ticker: (ADMP +0.3%)